Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: long-term results.

@article{Locatelli1999SubcutaneousAO,
  title={Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: long-term results.},
  author={Maria Cristina Locatelli and G. Facendola and Giorgio Pizzocaro and Luigi Piva and Cristina Pegoraro and Enrico Bobbio Pallavicini and A. Signaroldi and Maurizio Meregalli and F. Lombardi and Giordano Domenico Beretta and F Scanzi and Roberto Labianca and G. M. Dallavalle and Gino Luporini},
  journal={Cancer detection and prevention},
  year={1999},
  volume={23 2},
  pages={172-6}
}
Clinical data have supported the combination of subcutaneous r-interleukin-2 (rIL-2) and r-interferon-alpha (rIFN-alpha) as a promising combination for advanced renal cell carcinoma (RCC), with a reduced toxicity. We evaluated the activity and safety of this outpatient immunotherapy and report on the clinical results and the long-term survival analysis. Objective responses was observed in 9 of 50 (18%) patients, 6 of whom (12%) achieved a complete response. Overall median survival is 12 months… CONTINUE READING

From This Paper

Topics from this paper.
1 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…